Page last updated: 2024-09-05

lenalidomide and Recrudescence

lenalidomide has been researched along with Recrudescence in 301 studies

Research

Studies (301)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (11.30)	29.6817
2010's	231 (76.74)	24.3611
2020's	36 (11.96)	2.80

Authors

Authors	Studies
Alexander, M; Baculi, F; Carmichael, J; Cathers, B; Correa, M; Daniel, T; Ebinger, K; Grant, V; Hamann, LG; Hansen, JD; Harris, R; Havens, CG; Huang, D; Kercher, T; Khambatta, G; LeBrun, LA; Leftheris, K; Leisten, J; Lopez-Girona, A; Mendy, D; Moghaddam, M; Nagy, MA; Narla, RK; Piccotti, J; Plantevin, V; Tang, Y; Vessey, R; Whitefield, B	1
Chim, CS; Kumar, S; Kwong, YL; Ngai, C; Wong, VKC	1
Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M	1
Aldaoud, A; Behlendorf, T; Dechow, T; Eschenburg, H; Grebhardt, S; Groschek, M; Hansen, R; Knauf, W; Potthoff, K; Siebenbach, HU; Söling, U; Vannier, C	1
Chandar, R; Meena, S; Raj, R; Ramakrishnan, B; Uppuluri, R; Varla, H; Vellaichamy Swaminathan, V	1
Aoki, J; Fukuda, T; Inamoto, Y; Ito, A; Kim, SW; Takeda, W; Tanaka, T; Watanabe, M	1
Akiyama, H; Fujimori, C; Hagino, T; Hidai, H; Kurimoto, M; Motomura, S; Murai, Y; Osanai, S; Saga, R; Sano, S	1
Garcia-Horton, V; Guyot, P; Lin, PL; Richter, J; Sievert, M; Singh, E; Taiji, R; Zhou, ZY	1
Atrash, S; Bhutani, M; Druhan, LJ; Fesenkova, K; Foureau, DM; Friend, R; Guo, F; Norek, S; Paul, B; Pineda-Roman, M; Rigby, K; Robinson, M; Symanowski, JT; Tucker, MR; Usmani, SZ; Varga, C; Voorhees, PM	1
Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R	1
Amatangelo, M; Arnao, M; Bahlis, NJ; Berdeja, JG; Casas-Avilés, I; Gong, J; Karanes, C; Katz, J; Kim, K; Lamba, M; Li, S; Lonial, S; Maciag, P; Martinez-Lopez, J; Mateos, MV; Oriol, A; Orlowski, RZ; Pawlyn, C; Peluso, T; Pierce, DW; Poon, J; Popat, R; Pourdehnad, M; Quach, H; Ramasamy, K; Richardson, PG; Rodríguez Otero, P; Spirli, A; Trudel, S; Vangsted, AJ; Wong, L	1
Alexanian, R; Feng, L; Johnson, RJ; Lee, HC; Morphey, A; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, ML; Weber, DM; Wesson, ET	1
Bang, SM; Cho, SH; Do, YR; Eom, HS; Jo, JC; Kim, HJ; Kim, J; Kim, JS; Kim, K; Kim, MK; Kim, SH; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Lee, Y; Lim, SN; Min, CK; Mun, YC; Park, SK; Park, Y; Shin, HJ; Yi, JH; Yoon, DH; Yoon, SS	1
Ardoino, I; Baldini, L; Cafro, AM; Carniti, C; Corradini, P; Corso, A; Crippa, C; Galli, M; Gherlinzoni, F; Marcatti, M; Montefusco, V; Nozza, A; Patriarca, F; Pezzatti, S; Sammassimo, S; Zambello, R	1
Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS	1
Akashi, K; Choi, I; Iwasaki, H; Kamimura, T; Miyamoto, T; Mori, Y; Muta, T; Ogawa, R; Tanimoto, K; Yamasaki, S; Yoshimoto, G	1
Lesokhin, AM; Wills, B; Wudhikarn, K	1
Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P	1
Palazzo, G	1
Aitchison, R; Dimopoulos, MA; Gavriatopoulou, M; Hajek, R; Jelinek, T; Jenner, MW; Kastritis, E; Katodritou, E; Kothari, J; Kotsopoulou, M; Maouche, N; Minarik, J; Ntanasis-Stathopoulos, I; Pika, T; Plonkova, H; Ramasamy, K; Terpos, E; Vallance, GD; Zomas, A	1
Camilleri, M; Checkley, A; Pomplun, S; Rabin, N; Richards, H; Wilson, A	1
Epperla, N; Hanel, W	1
Anderson, LD; Chen, W; Fuda, FS; Gagan, J; Germans, SK; Jaso, JM; Koduru, P; Kulak, O; Oliver, D; Patel, P	1
Anderson, KC; Beksac, M; Belch, A; Dimopoulos, MA; Einsele, H; Ganetsky, A; Grosicki, S; Jou, YM; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Reece, D; Richardson, PG; Röllig, C; San-Miguel, J; Shpilberg, O; Singhal, AK; Spencer, A; Špička, I; Taniwaki, M; Walter-Croneck, A; Weisel, K; White, D; Wu, KL	1
Bang, SM; Do, YR; Eom, HS; Jo, JC; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Lee, Y; Lim, SN; Min, CK; Mun, YC; Park, SK; Park, Y; Shin, HJ; Yi, JH; Yoon, DH; Yoon, SS	1
Antonioli, E; Barilà, G; Bonalumi, A; Buda, G; Cavo, M; Cea, M; di Giovanni Bezzi, C; Dozza, L; Furlan, A; Mancuso, K; Martello, M; Marzocchi, G; Pantani, L; Petrini, M; Quaresima, M; Rizzello, I; Rocchi, S; Scalese, M; Staderini, M; Tacchetti, P; Zamagni, E	1
Beksaç, M; Mikhael, J; Richardson, PG; Špička, I	1
Avet-Loiseau, H; Bahlis, NJ; Benboubker, L; Casneuf, T; Chari, A; Cochrane, T; Cook, G; Dimopoulos, MA; Iida, S; Joy Ho, P; Kaufman, JL; Kim, JS; Kim, K; Kobos, R; Krevvata, M; Leiba, M; Magen, H; Miles Prince, H; Moreau, P; Morton, J; O'Rourke, L; Oriol, A; San-Miguel, J; Sutherland, HJ; Takezako, N; Trivedi, S; Ukropec, J; Usmani, SZ; White, D	1
Capalbo, S; Cascavilla, N; Citiso, S; Curci, P; De Francesco, R; De Risi, C; Di Renzo, N; Falcone, AP; Germano, C; Giannotta, A; Greco, A; Greco, G; Guarini, A; Mazza, P; Mele, A; Mele, G; Miccolis, R; Morciano, MR; Offidani, M; Palazzo, G; Palumbo, G; Pastore, D; Pavone, V; Prete, E; Reddiconto, G; Rizzi, R; Sabatelli, S; Sanpaolo, G; Sibilla, S; Specchia, G; Tarantini, G; Tonialini, L; Vergine, C	1
Atanesyan, L; Cairns, DA; Chown, S; Cook, G; Croft, J; Davies, FE; Drayson, MT; Ellis, S; Gregory, WM; Houlston, RS; Hunter, H; Jackson, G; Jenner, MW; Kaiser, MF; Karunanithi, K; Lindsay, J; Morgan, GJ; Owen, RG; Price, A; Savola, S; Sharp, K; Sherborne, AL	1
Bolaman, AZ; Eroğlu Küçükerdiler, H; Ertop, Ş; Sahip, B; Sargın, G; Selim, C; Turgutkaya, A; Yavaşoğlu, İ	1
Americo, AD; Arcuri, LJ	1
Bahlis, NJ; Ben-Yehuda, D; Carson, R; Cook, G; Dimopoulos, MA; Fastenau, J; Garvin, W; Goldschmidt, H; Gries, KS; Grosicki, S; Oriol, A; Plesner, T; Qin, X; Rabin, N; Renaud, T; San-Miguel, J; Suzuki, K; Yoon, SS	1
Cheng, Z; Feng, L; He, F; Wei, R; Wu, Y; Xiao, M; Zhao, G	1
Ai, L; Guo, T; Hu, Y; Jiang, H; Li, C; Lin, Z; Liu, L; Mei, H; Qian, Q; Sun, Y; Tang, L; Wang, J; Wu, J; Wu, Y; Xia, L	1
Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D	1
Basset, M; Benner, A; Dittrich, T; Goldschmidt, H; Hegenbart, U; Hose, D; Jauch, A; Kimmich, CR; Krzykalla, J; Müller-Tidow, C; Schönland, SO; Schreck, N; Seckinger, A; Veelken, K	1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E	1
Brown, JR; Itchaki, G	1
de Wit, E; Moreau, P	1
Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L	1
Cook, M; Denman, J; Manavi, K	1
Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D	1
Casadebaig Bravo, ML; Drach, J; Fu, T; Goy, A; Habermann, TM; Kalayoglu Besisik, S; Luigi Zinzani, P; Ramchandren, R; Takeshita, K; Tuscano, JM; Witzig, TE; Zhang, L	1
Chung, YJ; Jung, SH; Kim, SH; Kim, TW; Lee, M; Lee, SE; Min, CK; Yim, SH	1
Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G	1
Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M	1
Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F	1
Blair, HA	1
Guo, H; Sun, X; Wang, B; Xu, W	1
Clifton-Hadley, L; Counsell, N; Cwynarski, K; Gohil, SH; Maciocia, N; Nathwani, AC; Patrick, P; Pettitt, A; Roberts, T; Smith, P	1
Alexeeva, J; Arcaini, L; Belada, D; Biyukov, T; Cabeçadas, J; Campo, E; Casadebaig Bravo, ML; Jurczak, W; Lamy, T; Mayer, J; Morschhauser, F; Patturajan, M; Pileri, SA; Radford, J; Rule, S; Trnĕný, M; Walewski, J	1
Dahl, C; Eskelund, CW; Geisler, CH; Grønbæk, K; Hutchings, M; Jerkeman, M; Kolstad, A; Kuitunen, H; Laurell, A; Niemann, CU; Pedersen, LB; Räty, R; Toldbod, H; Wader, KF	1
Chosidow, O; Drahy, F; Grootenboer-Mignot, S; Ingen-Housz-Oro, S; Wolkenstein, P	1
Moreau, P; Touzeau, C	1
Alhyari, L; Cherry, M; Ibrahimi, S; Mukherjee, S; Scordino, T; Vidal, G	1
Cheson, BD; Khan, N; Ramzi, P; Skarbnik, A; Trivedi, N; Ujjani, C; Wang, H	1
Belickova, M; Cmunt, E; Fuchs, O; Jonasova, A; Michalova, K; Minarik, L; Moudra, A; Neuwirtova, R; Polackova, H; Siskova, M; Stopka, T; Zemanova, Z	1
Bensinger, W; Blaedel, J; Dimopoulos, M; Maisnar, V; Mateos, MV; Minarik, J; Moreau, P; Obreja, M; Wang, M	1
Dimopoulos, MA; Huang, SY; Iida, S; Kosugi, H; Matsumoto, M; Okamoto, S; Qi, M; Qin, X; Shinagawa, A; Suzuki, K; Takezako, N; Yoon, SS	1
Adamopoulos, I; Aktypi, A; Anagnostopoulos, A; Briasoulis, E; Delimpasi, S; Douka, V; Fotiou, D; Giannakoulas, N; Giannopoulou, E; Gogos, D; Hatzimichael, E; Katodritou, E; Kioumi, A; Kokoviadou, K; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Megalakaki, A; Nikolaou, E; Papadaki, E; Pappa, V; Repousis, P; Spanoudakis, E; Symeonidis, A; Terpos, E; Timotheatou, D; Vasilopoulos, G; Zikos, P	1
Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E	1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Park, SS; Ryu, DB; Yoon, JH	1
Nohgawa, M; Oka, S; Ono, K	1
Chen, L; Chen, N; Choi, K; Damato, B; Formaker, P; Fraser, EJ; Gangoiti, J; Geng, H; Hwang, J; Killea, P; Kurhanewicz, J; Li, J; Lowell, C; Munster, PN; Rubenstein, JL; Sharma, J; Sneed, PK; Treseler, P; Ventura, J; Wang, X	1
Illerhaus, G; Kasenda, B; Schorb, E	1
Jiang, J; Wan, N; Wang, S; Zhang, L; Zhang, TT; Zhang, Z	1
Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS	1
Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F	1
Moritz, RKC; Neufeld, M; Sunderkötter, C	1
Döhner, H; Fiedler, W; Hütter-Krönke, ML; Krauter, J; Kündgen, A; Schlenk, RF; von Lilienfeld-Toal, M	1
Dueck, AC; Hayman, S; Kanate, AS; Lonial, S; Manola, J; Mikhael, J; Oettel, K; Rajkumar, SV	1
Lamb, YN	1
Andre, M; Bijou, F; Bonnet, C; Bouabdallah, K; Cartron, G; Casasnovas, RO; de Guibert, S; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Maerevoet, M; Molina, L; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Ruminy, P; Salles, GA; Tilly, H; Van Den Neste, E; Van Eygen, K; Van Hoof, A; Zachee, P	1
Avet-Loiseau, H; Azais, I; Barrier, J; Bauwens, D; Bobin, A; Bonnin, A; Bouyier, S; Bridoux, F; Brigaud, A; Daras, C; Dieval, C; Diolez, J; Durand, G; Fleck, E; Fouquet, G; Franques, P; Fuzibet, JG; Gardeney, H; Gil, A; Gruchet, C; Guidez, S; Javaugue, V; Legros, L; Leleu, X; Levy, A; Machet, A; Moya, N; Plasse, F; Primault, S; Princet, I; Richez, V; Sabirou, F	1
Li, S; Maman, STD; Meng, XY; Xiao, YN	1
Brock, K; Cavenagh, J; Craddock, C; De Santo, C; Dennis, M; Ferguson, P; Hodgkinson, A; Ingram, W; Malladi, R; Mussai, F; Siddique, S; Slade, D; Wheat, R; Yap, C	1
Alahmadi, M; Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S	1
Fujiwara, T; Fukuhara, N; Furukawa, E; Harigae, H; Ichikawa, S; Kawajiri, A; Nakagawa, R; Onishi, Y; Onodera, K; Saito, K; Sano, S	1
Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S	1
Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM	1
Fujinami, H; Iida, S; Ishida, T; Ito, A; Kinoshita, S; Komatsu, H; Kusumoto, S; Marumo, Y; Masaki, A; Narita, T; Oshima, Y; Ri, M; Sasaki, H; Tachita, T; Totani, H; Yoshida, T	1
Aoyama, K; Arakawa, F; Morishige, S; Mouri, F; Nagafuji, K; Nakamura, T; Nishi, M; Ohshima, K; Osaki, K; Oya, S; Saruta, H; Seki, R; Yamaguchi, M; Yamasaki, Y	1
Bewersdorf, JP; Stahl, M; Zeidan, AM	1
Bailly, S; Bijou, F; Bonnet, C; Bouabdallah, R; Canioni, D; Cartron, G; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Meignin, V; Morschhauser, F; Nicolas-Virelizier, E; Salles, GA; Snauwaert, S; Thieblemont, C; Tilly, H; Van Eygen, K; Wu, KL	1
Liang, SH; Yeh, SP	1
Rajkumar, SV	1
Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Mori, F; Niimi, A; Ri, M; Suzuki, T; Yoshida, T	1
Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A	1
Chen, C; Chu, CM; Jiang, H; Jimenez-Zepeda, V; Kukreti, V; Masih-Khan, E; Reece, DE; Trudel, S; Young, T	1
Skarbnik, AP; Smith, MR	1
Badillo, M; Bejarano, M; Champlin, R; Chen, Y; Cheng, N; Desai, M; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hosing, C; Kwak, L; Neelapu, SS; Newberry, KJ; Oki, Y; Pro, B; Romaguera, J; Shah, J; Thomas, S; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zhang, L	1
Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L	1
Chang, MN; Hou, W; Jung, SH; Li, Y	1
Mahindra, A; Saini, N	1
Al-Ali, HK; Beck, J; Edelmann, T; Hebenstreit, K; Heyn, S; Hoffmann, FA; Jäkel, N; Lange, T; Mohren, M; Niederwieser, D; Pönisch, W; Röhrborn, R; Schmalfeld, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T	1
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G	1
Czuczman, MS; Habermann, TM; Li, J; Lossos, IS; Pietronigro, D; Reeder, CB; Tuscano, JM; Vose, JM; Witzig, TE; Zinzani, PL	1
Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P	1
Mark, TM; Meadows, JP	1
Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K	1
Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L	1
Czuczman, MS; Haioun, C; Li, J; Polikoff, J; Prandi, K; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zhang, L; Zinzani, PL	1
Kharfan-Dabaja, MA; Komrokji, RS; Zeidan, AM	1
Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W	1
Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L	1
Alousi, A; Di Stasi, A; Hosing, C; Keating, M; Mehta, RS; O'Brien, S; Rezvani, K; Shah, N; Shpall, EJ; Wierda, W	1
Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T	1
Cavallo, F; Genadieva-Stavric, S; Palumbo, A	1
Agostinelli, C; Argnani, L; Broccoli, A; Celli, M; Pellegrini, C; Pileri, S; Zinzani, PL	1
Beaven, AW; Bejot, C; Bhattacharyya, P; Carini, C; Chow, KF; Donato, ML; Feldman, T; Gadaleta, G; Goy, A; Kdiry, S; Mato, AR; Pecora, AL; Protomastro, EA; Rowley, SD; Smith, J; Stives, S; Timberg, M; Valentinetti, M; Yang, X; Yannotti, KM	1
Govindaraj, C; Kong, YY; Madondo, M; Plebanski, M; Tan, P; Wei, A	1
Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ	1
Kalampokis, I; Rabinovich, CE	1
Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ	1
Agostino, NM; Gheith, S; Nair, R; Popescu, D	1
Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M	1
Bartlett, NL; Blum, KA; Cheson, BD; Johnson, J; Jung, SH; LaCasce, A; Morrison, VA; Pitcher, BN	1
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H	1
Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P	1
Andritsos, LA; Browning, R; Byrd, JC; Flynn, J; Gao, Y; Harper, E; Jiang, Y; Johnson, AJ; Jones, J; Kefauver, C; Maddocks, K; Phelps, MA; Poi, M; Rozewski, DM; Ruppert, AS	1
Mateos, MV; Miguel, JF	1
Kumar, S; Singla, A	1
Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL	1
Hobeika, L; Self, SE; Velez, JC	1
Gałązka, K; Gruchała, A; Jurczak, W; Krawczyk, K; Skotnicki, AB	1
Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K	1
Blin, N; Caristan, A; Connault, J; Duhamel, E; Graveleau, J; Hamidou, M; Le Gouill, S; Lestang, E; Maisonneuve, H; Masseau, A; Moreau, P; Néel, A; Touzeau, C	1
Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L	1
Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H	1
Cai, H; Cai, QQ; Cao, XX; Li, J; Wang, C; Zhou, DB	1
Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N	1
Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A	1
Nakaseko, C; Sakaida, E; Takeda, Y	1
Adusumilli, M; Andritsos, LA; Blum, KA; Byrd, JC; Cardone, MH; Doykin, C; Flynn, J; Grever, MR; Jiang, Y; Johnson, AJ; Jones, JA; Maddocks, K; Phelps, MA; Pierceall, WE; Rozewski, D; Wei, L; Zhao, Y	1
Holstein, SA; Laubach, JP; McCarthy, PL; Richardson, PG	1
Casanova, M; García-Sanz, R; Labrador, J; Pastor, M; Provencio, M; Quero-Blanco, C; Rueda, A; Salar, A	1
Rosen, ST; Siddiqi, T	1
Areethamsirikul, N; Reece, DE	1
Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S	1
Anderson, KC; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, M; Einsele, H; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Palumbo, A; Poulart, V; Reece, D; Richardson, P; Röllig, C; San-Miguel, J; Singhal, A; Spencer, A; Spicka, I; Taniwaki, M; Walter-Croneck, A; White, D; Wu, KL	1
Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R	1
Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S	1
Abe, Y; Ikeda, M; Meshitsuka, S; Miyazaki, K; Shingaki, S; Suzuki, K; Tsukada, N; Yoshiki, Y	1
Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O	1
Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H	1
Robak, T; Smolewski, P; Witkowska, M	1
Bullement, A; Dickens, E; Elvidge, J; Gooding, S; Lau, IJ; Lee, D; Ramasamy, K; Roberts, P; Sheikh, M; Wong, J	1
Berardi, M; Biagioli, T; Bosi, A; Brogi, M; Caldini, A; Nozzoli, C; Staderini, M; Terreni, A	1
Alemayehu, WG; Bos, GM; Broijl, A; Cornelisse, PB; de Weerdt, O; Kersten, MJ; Levin, MD; Lokhorst, H; Meijer, E; Sonneveld, P; Stevens-Kroef, M; Tanis, BC; Vellenga, E; Wijermans, PW; Wittebol, S	1
Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T	1
Buhler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Stilgenbauer, S; Wendtner, CM; Zhang, J	1
Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J	1
Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W	1
Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A	1
Aurran-Schleinitz, T; Bühler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gregory, SA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Rassenti, L; Stilgenbauer, S; Trentin, L; Wendtner, CM; Zhang, J	1
Adami, F; Angelini, A; Cacciavillani, L; Cianci, A; De Lazzari, M; Fedrigo, M; Giorgi, B; Iliceto, S; Migliore, F; Perazzolo Marra, M; Tarantini, G; Thiene, G; Valente, M	1
Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P	1
Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U	1
Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E	1
Chen, L; de Miranda, NF; Dlugosz-Danecka, M; Galazka, K; Jurczak, W; Machaczka, M; Mansouri, L; Morin, RD; Pan-Hammarström, Q; Peng, R; Rosenquist, R; Sander, B; Wasik, AM; Wu, C; Zhang, H	1
Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC	1
Bagacean, C; Bocsan, C; Ianotto, JC; Salaun, PY; Tempescul, A; Zdrenghea, M	1
Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E	1
Bettelli, S; Luminari, S; Maiorana, A; Salati, M; Tarantino, V	1
Hu, X; Liang, L; Liu, H; Yang, LP; Zhao, M; Zhu, YC	1
Avet-Loiseau, H; Ben-Yehuda, D; Bensinger, W; Dimopoulos, MA; Fonseca, R; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Kukreti, V; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, G; Minarik, J; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rosiñol, L; Siegel, D; Špička, I; Stewart, AK; Wang, M	1
Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I	1
Ahmadi, T; Arkenau, HT; Basse, L; Clemens, PL; de Boer, C; Gimsing, P; Guckert, ME; Khokhar, NZ; Krejcik, J; Lassen, U; Laubach, JP; Lemech, C; Lisby, S; Lokhorst, HM; Minnema, MC; Palumbo, A; Plesner, T; Richardson, PG; Sasser, AK; Wang, J; Yeh, H	1
Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R	1
Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G	1
Bakane, A; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R	1
Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N	1
Abe, Y; Fujiwara, H; Imaizumi, Y; Ishida, T; Ishizawa, K; Ito, S; Jo, T; Midorikawa, S; Moriuchi, Y; Nosaka, K; Ogura, M; Ohtsu, T; Otsuka, M; Ruiz, W; Taira, N; Tobinai, K; Tsukasaki, K; Yoshimitsu, M	1
Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS	1
Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH	1
Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M	1
Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F	1
Cavo, M; Mancuso, K; Pantani, L; Pezzi, A; Rizzello, I; Rocchi, S; Tacchetti, P; Zamagni, E; Zannetti, BA	1
Cabrera César, E; Fernández Aguirre, MC; González Fernández, A	1
Agarwal, A; Bhutani, M; Chow, E; Friend, R; Usmani, SZ; Voorhees, PM	1
Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T	1
Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E	1
Boudreault, JS; Moreau, P; Touzeau, C	1
Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C	1
Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A	1
Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R	1
Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I	1
Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S	1
Blum, KA; Byrd, JC; Dalton, JT; Farley, KL; Grever, MR; Hofmeister, CC; Johnson, AJ; Liu, Q; Muthusamy, N; Phelps, MA; Schaaf, LJ	1
Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB	1
Anderson, KC; Attal, M; Cavo, M; Gertz, MA; Giralt, S; Ludwig, H; Morgan, GJ	1
Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C	1
Berthou, C; De Braekeleer, M; Ianotto, JC; Marion, V; Morel, F; Tempescul, A	1
Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB	1
Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB	1
Meijer, E; Sonneveld, P	1
Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J	1
Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB	1
Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR	1
Barnett, DB; Boysen, M; Chung, H; Gajraj, E; Longson, C	1
Asch, J; Ford, CD; Konopa, K; Petersen, FB	1
Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB	1
San Miguel, JF	1
Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E	1
Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB	1
Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U	1
Böll, B; Borchmann, P; Engert, A; Hänel, M; Naumann, R; Reiners, KS; Topp, MS	1
Bilgrami, SA; Block, AW; Chanan-Khan, AA; Czuczman, MS; Hernandez-Ilizaliturri, F; Lawrence, D; Lawrence, W; Lee, K; Miller, A; Miller, KC; Sher, T; Sood, R; Whitworth, A; Wood, MT	1
Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E	1
Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S	1
Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Niscola, P; Perrotti, A; Siniscalchi, A; Tendas, A	1
Dimopoulos, MA; Jagannath, S; Lonial, S	1
Einsele, H; Kortuem, M	1
Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA	1
Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; van der Jagt, R; White, D	1
Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J	1
Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y	1
Becker, H; Blum, W; Byrd, JC; Chandler, JC; Curfman, J; Devine, SM; Garzon, R; Grever, MR; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Phelps, MA; Rozewski, DM; Schaaf, L; Walker, A; Whitman, SP; Yang, X	1
Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M	1
Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A	1
Guglielmelli, T; Palumbo, A; Petrucci, MT; Saglio, G	1
Anderson, K; Laubach, J; Richardson, P	1
Dimopoulos, MA; Terpos, E	1
Blaney, SM; Boyett, JM; Fangusaro, J; Goldman, S; Jakacki, R; Kun, LE; Macdonald, T; Packer, R; Pollack, IF; Schaiquevich, P; Stewart, CF; Wallace, D; Warren, KE	1
Adamson, PC; Ayello, J; Berg, SL; Blaney, SM; Cairo, MS; Chen, N; Ingle, AM; Lau, H; Russell, H	1
Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P	1
Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K	1
Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN	1
Lonial, S; Mitsiades, CS; Richardson, PG	1
Lyseng-Williamson, KA; Scott, LJ	1
Engelhardt, M; Finke, J; Jakob, T; Technau, K; Wäsch, R	1
Czuczman, MS; Deeb, G; Goy, A; Hernandez-Ilizaliturri, FJ; Macon, WR; Malik, F; Pileri, SA; Witzig, TE; Zinzani, PL	1
Argnani, L; Baccarani, M; Berti, E; Broccoli, A; Derenzini, E; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Zinzani, PL	1
Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A	1
Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P	1
Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F	1
Cheson, BD	1
Ishak, J; Rodrigues, F	1
Buckstein, R; Czuczman, MS; Ervin-Haynes, A; Li, J; Pietronigro, D; Polikoff, J; Reeder, CB; Vose, JM; Witzig, TE; Zinzani, PL	1
Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D	1
Fukushima, T; Iwao, H; Nakamura, T; Umehara, H	1
Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Zinzani, PL	1
Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J	1
Bartlett, NL; Blum, KA; Carson, KR; Cashen, AF; Fehniger, TA; Fenske, TS; Goy, A; Hurd, DD; Keppel, CR; Larson, S; Schneider, SE; Siegel, MJ; Trinkaus, K; Wagner-Johnston, ND	1
Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R	1
Balzarotti, M; Bonfichi, M; Bottelli, C; Brusamolino, E; De Luca, S; Fanin, R; Levis, A; Monagheddu, C; Orsucci, L; Pileri, SA; Ravelli, E; Ria, R; Rusconi, C; Sabattini, E; Salvi, F; Tucci, A; Vacca, A; Vitolo, U; Volpetti, S; Zaja, F	1
Ashida, T; Emoto, M; Hirase, C; Matsumura, I; Morita, Y; Ojima, M; Rai, S; Serizawa, K; Shimada, T; Taniguchi, Y; Tatsumi, Y; Yamaguchi, T	1
Banos, A; Baracco, F; Besson, C; Blanc, M; Cannas, G; Corm, S; Fenaux, P; Perrier, H; Prebet, T; Sibon, D; Slama, B; Vey, N; Wattel, E	1
Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C	1
Figueiredo, A; João, C; Martins, HF	1
Chang, H; Chen, MH; Qi, CX; Saha, MN	1
Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL	1
Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A	1
Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T	1
Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC	1
Ramchandren, R	1
Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L	1
Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA	1
Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B	1
Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C	1
Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K	1
Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA	1
Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T	1
Janakiraman, N; Munoz, J	1
Badillo, M; Bejarano, M; Bell, N; Byrne, C; Cabanillas, F; Champlin, R; Chen, W; Chen, Y; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hartig, K; Kwak, L; McLaughlin, P; Neelapu, SS; Newberry, KJ; Romaguera, J; Samaniego, F; Sun, L; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zeldis, J; Zhang, L	1
Dawar, R; Hernandez-Ilizaliturri, F	1
Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS	1
Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D	1
Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Burchert, A; Hansen, T; Hildebrandt, Y; Klyuchnikov, E; Kröger, N; Kropff, M; Pflüger, KH; Schilling, G; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR	1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S	1
Auer, RL; Bullard, SH; Carey, S; Eve, HE; Heise, CC; Mamidipudi, V; Radford, JA; Richardson, SJ; Rule, SA; Shi, T	1
Banglawala, S; Lentz, EM; Reece, DE; Seki, JT	1
Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA	1
Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I	1
Ludwig, H; Sonneveld, P	1
Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L	1
Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M	1
Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG	1
Corradini, P; Farina, L; Rezzonico, F; Spina, F	1
Suzuki, K	1
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F	1
Abraham, J; Asli, B; Banos, A; Brisseau, JM; Choquet, S; Decaux, O; Deplanque, G; Facon, T; Fermand, JP; Galicier, L; Godmer, P; Guichard, I; Haroche, J; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Marolleau, JP; Merlusca, L; Musset, L; Recher, C; Roussel, M; Royer, B; Sebban, C	1
Hattori, Y	1
Gibson, AD; Klem, J; Price, N; Reddy, GK	1
Bauters, F; Berthon, C; Facon, T; Guieze, R; Kuhnovsky, F; Leleu, X; Micol, JB; Moreau, AS; Terriou, L; Yakoub-Agha, I	1
Richardson, P	1
Kaufman, JL; Lonial, S; Sinha, R	1
Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J	1
Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB	1
Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J	1
Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ	1
Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG	1
Chanan-Khan, AA; Lee, K	1
Mehta, J; Singhal, S	1
Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R	1
Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB	1
Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB	1
Davies, FE; Morgan, GJ; Srikanth, M	1
D'Auria, F; Guariglia, R; Lerose, R; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O; Zonno, A	1

Reviews

54 review(s) available for lenalidomide and Recrudescence

Article	Year
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide	2020
Emerging therapies in mantle cell lymphoma. Journal of hematology & oncology, 2020, 06-17, Volume: 13, Issue:1 Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Recurrence; Salvage Therapy; Therapies, Investigational	2020
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity. American journal of clinical pathology, 2020, 11-04, Volume: 154, Issue:6 Topics: Adult; Antineoplastic Agents; Bone Marrow; Cytogenetic Analysis; Fatal Outcome; High-Throughput Nucleotide Sequencing; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Stem Cell Transplantation	2020
Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert opinion on biological therapy, 2020, Volume: 20, Issue:12 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Treatment Outcome	2020
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis. Annals of hematology, 2021, Volume: 100, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Network Meta-Analysis; Progression-Free Survival; Recurrence	2021
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:1 Topics: B-Cell Maturation Antigen; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin D; Immunologic Factors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Receptors, Chimeric Antigen; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine	2022
Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert opinion on investigational drugs, 2017, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thalidomide	2017
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. British journal of haematology, 2017, Volume: 179, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide	2017
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. PharmacoEconomics, 2018, Volume: 36, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide	2018
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. Drugs, 2017, Volume: 77, Issue:18 Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia	2017
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. Annals of hematology, 2018, Volume: 97, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prospective Studies; Proteasome Inhibitors; Recurrence; Survival Analysis; Thalidomide	2018
Ixazomib in the management of relapsed multiple myeloma. Future oncology (London, England), 2018, Volume: 14, Issue:20 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials as Topic; Dexamethasone; Disease Management; Glycine; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Recurrence	2018
Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood, 2018, 08-16, Volume: 132, Issue:7 Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nivolumab; Piperidines; Pyrazoles; Pyrimidines; Recurrence	2018
[Scleromyxedema]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2018, Volume: 69, Issue:11 Topics: Humans; Lenalidomide; Rare Diseases; Recurrence; Scleromyxedema	2018
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma. Drugs, 2018, Volume: 78, Issue:14 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Progression-Free Survival; Quality of Life; Recurrence; Treatment Failure	2018
Therapies for mantle cell lymphoma: current challenges and a brighter future. Discovery medicine, 2013, Volume: 15, Issue:82 Topics: Antibodies; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cyclin D1; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Thalidomide; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome	2013
Therapeutic strategies for the treatment of multiple myeloma. Discovery medicine, 2013, Volume: 15, Issue:83 Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide	2013
Management of double-refractory multiple myeloma. Current hematologic malignancy reports, 2013, Volume: 8, Issue:4 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide	2013
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current opinion in hematology, 2014, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Prognosis; Recurrence; Retreatment; Thalidomide; Transplantation, Homologous; Treatment Failure; Treatment Outcome	2014
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. Acta haematologica, 2014, Volume: 132, Issue:2 Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic	2014
New approaches to management of multiple myeloma. Current treatment options in oncology, 2014, Volume: 15, Issue:2 Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome	2014
Current challenges in the management of patients with relapsed/refractory multiple myeloma. Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2 Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide	2011
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2 Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; TOR Serine-Threonine Kinases	2011
Management of relapsed multiple myeloma after autologous stem cell transplant. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5 Topics: Autografts; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Stem Cell Transplantation; Thalidomide	2015
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4 Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome	2015
The risk of secondary primary malignancies after therapy for multiple myeloma. Leukemia & lymphoma, 2015, Volume: 56, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Incidence; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Retreatment; Risk; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome	2015
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide	2015
Treatment options for mantle cell lymphoma. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:16 Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Thalidomide	2015
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. Annals of hematology, 2016, Volume: 95, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Outcome Assessment, Health Care; Recurrence; Rituximab; Thalidomide	2016
Practical Considerations in Managing Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide	2017
Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert opinion on drug safety, 2017, Volume: 16, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2017
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. Expert review of hematology, 2017, Volume: 10, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2017
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. International journal of laboratory hematology, 2009, Volume: 31, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom	2009
New developments in the treatment of patients with multiple myeloma. The Netherlands journal of medicine, 2010, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide	2010
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia research, 2010, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic	2010
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European journal of haematology, 2010, Volume: 85, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide	2010
Multiple myeloma. Annual review of medicine, 2011, Volume: 62 Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2011
Treatment options for relapsed and refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-15, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide	2011
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs, 2011, Mar-26, Volume: 71, Issue:5 Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide	2011
New agents in follicular lymphoma. Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:2 Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment	2011
Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. Current opinion in oncology, 2012, Volume: 24 Suppl 2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Thalidomide	2012
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. The oncologist, 2012, Volume: 17, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide	2012
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best practice & research. Clinical haematology, 2012, Volume: 25, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytokines; Disease Management; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; T-Lymphocytes; Thalidomide; Treatment Outcome	2012
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? Leukemia research, 2012, Volume: 36 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors	2012
Current therapeutic strategy for multiple myeloma. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2 Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid	2013
[Thalidomide treatment in multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:5 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide	2003
[Thalidomide: mechanisms of action and new insights in hematology]. La Revue de medecine interne, 2005, Volume: 26, Issue:2 Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Forecasting; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrence; Thalidomide; Time Factors; Waldenstrom Macroglobulinemia	2005
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Seminars in hematology, 2005, Volume: 42, Issue:4 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide	2005
Novel treatment approaches for patients with multiple myeloma. Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:4 Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide	2006
The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network : JNCCN, 2007, Volume: 5, Issue:2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide	2007
Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clinical lymphoma & myeloma, 2007, Volume: 7 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Multiple Myeloma; Polyethylene Glycols; Recurrence; Survival Rate; Thalidomide; Treatment Outcome	2007
Lenalidomide in myeloma. Current treatment options in oncology, 2007, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide	2007
The treatment of relapsed and refractory multiple myeloma. Hematology. American Society of Hematology. Education Program, 2007 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide	2007
An update on drug combinations for treatment of myeloma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome	2008

Trials

108 trial(s) available for lenalidomide and Recrudescence

Article	Year
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide	2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European journal of haematology, 2022, Volume: 108, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2022
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pandemics; Recurrence	2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine, 2023, Sep-14, Volume: 389, Issue:11 Topics: Administration, Oral; Antibodies; Antineoplastic Agents; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Ubiquitin-Protein Ligases	2023
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. American journal of hematology, 2019, Volume: 94, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Salvage Therapy; Thalidomide	2019
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). Annals of hematology, 2020, Volume: 99, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Republic of Korea; Survival Rate	2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). American journal of hematology, 2020, Volume: 95, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide	2020
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma. International journal of hematology, 2020, Volume: 111, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Treatment Outcome	2020
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future oncology (London, England), 2020, Volume: 16, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide	2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of hematology, 2020, Volume: 99, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate	2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood cancer journal, 2020, 09-04, Volume: 10, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate	2020
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematological oncology, 2021, Volume: 39, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate	2021
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood cancer journal, 2020, 11-03, Volume: 10, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human; Cytogenetic Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Survival Rate; Translocation, Genetic	2020
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. British journal of haematology, 2021, Volume: 194, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Patient Reported Outcome Measures; Progression-Free Survival; Quality of Life; Recurrence; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome	2021
Frontiers in immunology, 2021, Volume: 12 Topics: Humans; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Remission Induction	2021
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. British journal of haematology, 2017, Volume: 178, Issue:6 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulins; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2017
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. American journal of hematology, 2017, Volume: 92, Issue:10 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia	2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British journal of haematology, 2018, Volume: 180, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2018
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Haematology, 2018, Volume: 5, Issue:3 Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome	2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood advances, 2018, 04-10, Volume: 2, Issue:7 Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Rituximab; Salvage Therapy	2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE st Journal of hematology & oncology, 2018, 04-04, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Recurrence	2018
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood cancer journal, 2018, 05-01, Volume: 8, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Treatment Outcome	2018
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International journal of hematology, 2018, Volume: 108, Issue:3 Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2018
Low frequency of CD3 Annals of hematology, 2018, Volume: 97, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4 Antigens; Dexamethasone; Female; Humans; Infections; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; NK Cell Lectin-Like Receptor Subfamily B; Recurrence; Risk Factors	2018
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood advances, 2018, 07-10, Volume: 2, Issue:13 Topics: Aged; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma; Maintenance Chemotherapy; Male; Middle Aged; Recurrence; Rituximab; Survival Rate	2018
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood cancer journal, 2018, 08-29, Volume: 8, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Monitoring; Female; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Renal Insufficiency; Survival Analysis; Treatment Outcome	2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. Leukemia, 2019, Volume: 33, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence	2019
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 03-01, Volume: 37, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Failure; United Kingdom; Young Adult	2019
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. The Lancet. Haematology, 2019, Volume: 6, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Recurrence; Survival Rate; Treatment Outcome	2019
Sorafenib in patients with refractory or recurrent multiple myeloma. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome	2013
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia, 2013, Volume: 27, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Rituximab; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2013
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. British journal of haematology, 2013, Volume: 162, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Thalidomide	2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, Aug-22, Volume: 122, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-10, Volume: 31, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide	2013
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Recurrence; Thalidomide; Treatment Outcome	2013
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood, 2014, Mar-06, Volume: 123, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome	2014
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of hematology, 2014, Volume: 93, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Drug Resistance, Neoplasm; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Thalidomide; Thrombocytopenia; Vorinostat	2014
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. British journal of haematology, 2014, Volume: 166, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome	2014
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American journal of hematology, 2014, Volume: 89, Issue:8 Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide	2014
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. British journal of haematology, 2014, Volume: 166, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Sirolimus; Thalidomide; Treatment Outcome	2014
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia & lymphoma, 2015, Volume: 56, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome	2015
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leukemia research, 2014, Volume: 38, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Thalidomide; Treatment Outcome	2014
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood cancer journal, 2014, Nov-07, Volume: 4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England journal of medicine, 2015, Jan-08, Volume: 372, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide	2015
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). American journal of hematology, 2015, Volume: 90, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Recurrence; Thalidomide; Treatment Outcome; Tumor Lysis Syndrome	2015
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:6 Topics: Administration, Metronomic; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Early Termination of Clinical Trials; Female; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Prospective Studies; Recurrence; Retreatment; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome; Young Adult	2015
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. The New England journal of medicine, 2015, Aug-13, Volume: 373, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Receptors, Immunologic; Recurrence; Signaling Lymphocytic Activation Molecule Family; Thalidomide	2015
Lenalidomide is safe and active in Waldenström macroglobulinemia. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome; Waldenstrom Macroglobulinemia	2015
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Journal of hematology & oncology, 2015, Sep-04, Volume: 8 Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2015
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica, 2016, Volume: 101, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lenalidomide; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome	2016
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. International journal of hematology, 2016, Volume: 103, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leukemia & lymphoma, 2016, Volume: 57, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2016
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome	2016
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. The Lancet. Haematology, 2016, Volume: 3, Issue:3 Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Peripheral; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Young Adult	2016
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood cancer journal, 2016, Mar-11, Volume: 6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53	2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio BMC cancer, 2016, Apr-25, Volume: 16 Topics: Adult; Aged; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2016
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Creatinine; Dexamethasone; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Renal Insufficiency; Thalidomide	2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, 2016, 09-01, Volume: 128, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Risk Factors; Survival Rate; Thalidomide	2016
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leukemia & lymphoma, 2017, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome	2017
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood, 2016, 10-06, Volume: 128, Issue:14 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 11-10, Volume: 34, Issue:32 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Quality of Life; Recurrence; Thalidomide; Young Adult	2016
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Volume: 34, Issue:34 Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Endpoint Determination; Female; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome	2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine, 2016, 10-06, Volume: 375, Issue:14 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2016
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. International journal of hematology, 2017, Volume: 105, Issue:3 Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Leukopenia; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome	2017
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leukemia & lymphoma, 2017, Volume: 58, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine	2017
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. International journal of hematology, 2017, Volume: 105, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Leukopenia; Male; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia	2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British journal of haematology, 2017, Volume: 177, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Recurrence; Thalidomide	2017
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. British journal of haematology, 2017, Volume: 177, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide; Treatment Outcome	2017
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Therapeutic drug monitoring, 2008, Volume: 30, Issue:5 Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; Spectrometry, Mass, Electrospray Ionization; Thalidomide; Time Factors	2008
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. British journal of haematology, 2009, Volume: 145, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Treatment Outcome	2009
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European journal of haematology, 2009, Volume: 82, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome	2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 2009, Jul-23, Volume: 114, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Biological; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome	2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide	2009
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome	2009
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer, 2010, Jan-01, Volume: 116, Issue:1 Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recurrence; Retreatment; Skin Neoplasms; Thalidomide	2010
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. British journal of haematology, 2010, Volume: 148, Issue:3 Topics: Adult; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Staging; Recurrence; Thalidomide; Treatment Outcome; Young Adult	2010
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia & lymphoma, 2010, Volume: 51, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytogenetics; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prognosis; Recurrence; Risk; Thalidomide; Treatment Outcome	2010
Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience. Annals of hematology, 2011, Volume: 90, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2011
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer, 2010, Aug-15, Volume: 116, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Thalidomide	2010
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer, 2010, Oct-01, Volume: 116, Issue:19 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Thalidomide	2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-20, Volume: 28, Issue:33 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Thalidomide	2010
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Nov-01, Volume: 16, Issue:21 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Double-Blind Method; Humans; Lenalidomide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Testosterone; Thalidomide	2010
Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. British journal of haematology, 2011, Volume: 152, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2011
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Recurrence; Thalidomide; Young Adult	2011
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Immunity, Cellular; Infant; Lenalidomide; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neoplasms; Recurrence; Salvage Therapy; Thalidomide; Young Adult	2011
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. International journal of hematology, 2011, Volume: 93, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Compassionate Use Trials; Cross-Sectional Studies; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Registries; Retrospective Studies; Salvage Therapy; Spain; Survival Rate; Thalidomide	2011
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leukemia & lymphoma, 2011, Volume: 52, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neutropenia; Prospective Studies; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome	2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. British journal of haematology, 2011, Volume: 154, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Thalidomide; Treatment Outcome	2011
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Rituximab; Thalidomide	2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & lymphoma, 2012, Volume: 53, Issue:3 Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine	2012
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood, 2011, Nov-10, Volume: 118, Issue:19 Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL17; Chemokine CCL22; Disease-Free Survival; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Stem Cell Transplantation; Thalidomide	2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica, 2012, Volume: 97, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neovascularization, Pathologic; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome; Tumor Microenvironment	2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. British journal of haematology, 2012, Volume: 156, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematinics; Humans; Karyotype; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Thalidomide; Treatment Failure; Treatment Outcome	2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2012, Volume: 53, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome	2012
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leukemia & lymphoma, 2012, Volume: 53, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Quality of Life; Recurrence; Spain; Surveys and Questionnaires; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome	2012
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood, 2012, May-17, Volume: 119, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Thalidomide; Treatment Outcome	2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2012
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Thalidomide; Treatment Outcome	2012
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. British journal of haematology, 2012, Volume: 158, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphatidylinositol 3-Kinase; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Thalidomide; Treatment Outcome	2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. The Lancet. Oncology, 2012, Volume: 13, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Rituximab; Thalidomide	2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone marrow transplantation, 2013, Volume: 48, Issue:3 Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Young Adult	2013
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. British journal of haematology, 2012, Volume: 159, Issue:2 Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Interleukin-10; Interleukin-12 Subunit p40; Lenalidomide; Leukocyte Count; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Sex Characteristics; Sex Factors; Survival Rate; Thalidomide; United Kingdom	2012
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis research & therapy, 2012, Dec-07, Volume: 14, Issue:6 Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Middle Aged; Neutropenia; Pilot Projects; Recurrence; Remission Induction; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Thalidomide; Treatment Outcome; Vomiting	2012
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-10, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Humans; Immunologic Factors; Infections; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Time Factors; Treatment Outcome	2013
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Thalidomide; Venous Thrombosis	2006
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Thalidomide	2006
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide	2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide	2007

Other Studies

139 other study(ies) available for lenalidomide and Recrudescence

Article	Year
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma. Journal of medicinal chemistry, 2020, 07-09, Volume: 63, Issue:13 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Mice; Multiple Myeloma; Recurrence; Stereoisomerism; Treatment Failure; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays	2020
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. European journal of haematology, 2022, Volume: 108, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Management; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Quality of Life; Recurrence; Retreatment; Treatment Outcome	2022
Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect. Pediatric transplantation, 2022, Volume: 26, Issue:5 Topics: Blood Donors; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocytes; Recurrence; Retrospective Studies	2022
Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation. Hematological oncology, 2023, Volume: 41, Issue:3 Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Recurrence; Retrospective Studies	2023
[Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Multiple Myeloma; Plasmacytoma; Recurrence; Thrombotic Microangiopathies	2022
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma. Cancer medicine, 2023, Volume: 12, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence	2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica, 2023, 11-01, Volume: 108, Issue:11 Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous	2023
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. British journal of haematology, 2020, Volume: 188, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Treatment Outcome	2020
[Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.] Recenti progressi in medicina, 2020, Volume: 111, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Oligopeptides; Plasma Cells; Recurrence	2020
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma. British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; Immunocompromised Host; Immunomodulation; Leishmania donovani; Leishmaniasis, Visceral; Lenalidomide; Male; Mediterranean Region; Multiple Myeloma; Pancytopenia; Phosphorylcholine; Recurrence; Renal Dialysis; Travel-Related Illness	2020
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. International journal of hematology, 2021, Volume: 113, Issue:1 Topics: Aged; Aged, 80 and over; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Frailty; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Treatment Failure; Treatment Outcome	2021
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). Annals of hematology, 2021, Volume: 100, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate	2021
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 2021, Volume: 35, Issue:7 Topics: Cyclin D1; DNA Copy Number Variations; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Nerve Tissue Proteins; Prognosis; Recurrence	2021
Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events Turkish journal of haematology : official journal of Turkish Society of Haematology, 2021, 02-25, Volume: 38, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Drugs, Generic; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Odds Ratio; Recurrence; Retreatment; Treatment Outcome	2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. European journal of haematology, 2021, Volume: 107, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous	2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. British journal of haematology, 2021, Volume: 195, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Progression-Free Survival; Recurrence; Retrospective Studies	2021
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid	2017
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement. Annals of hematology, 2017, Volume: 96, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous	2017
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. International journal of STD & AIDS, 2017, Volume: 28, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HIV Seropositivity; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Paraproteinemias; Recurrence; Thalidomide; Treatment Outcome	2017
Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. Haematologica, 2017, Volume: 102, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating MicroRNA; Dexamethasone; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Reproducibility of Results; Retreatment; ROC Curve; Thalidomide; Treatment Outcome	2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). Journal of hematology & oncology, 2017, 11-02, Volume: 10, Issue:1 Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Thalidomide	2017
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood, 2018, 02-01, Volume: 131, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2018
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retreatment; Treatment Outcome	2018
Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. JAMA dermatology, 2018, 04-01, Volume: 154, Issue:4 Topics: Adult; Chronic Disease; Drug Substitution; Erythema Multiforme; Female; Humans; Immunologic Factors; Lenalidomide; Recurrence; Thalidomide	2018
Sustained response to lenalidomide for early relapsed marginal zone lymphoma. Blood cells, molecules & diseases, 2018, Volume: 71 Topics: Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymph Nodes; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neck; Recurrence; Tomography, X-Ray Computed; Treatment Outcome	2018
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients). Leukemia research, 2018, Volume: 69 Topics: Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Czech Republic; Erythropoietin; Female; Genes, p53; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prednisone; Recurrence; Remission Induction; Risk Factors	2018
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Annals of hematology, 2018, Volume: 97, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide	2018
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide. Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:6 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2018
Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma. Clinical therapeutics, 2018, Volume: 40, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Markov Chains; Middle Aged; Multiple Myeloma; Quality-Adjusted Life Years; Recurrence; United States	2018
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ open, 2018, 07-23, Volume: 8, Issue:7 Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States	2018
Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\ refractory multiple myeloma: a real-life experience Turkish journal of medical sciences, 2018, Aug-16, Volume: 48, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Pregnancy; Prognosis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey	2018
Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. Haematologica, 2019, Volume: 104, Issue:2 Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Retreatment; Treatment Outcome	2019
Carfilzomib weekly 20/56 mg/m American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Recurrence; Salvage Therapy	2019
Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data. BioMed research international, 2018, Volume: 2018 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate	2018
Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Retrospective Studies; Treatment Outcome	2019
Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Annals of hematology, 2019, Volume: 98, Issue:8 Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dexamethasone; Drug Evaluation; Female; Ganciclovir; Humans; Immunocompromised Host; Lenalidomide; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Valganciclovir; Virus Activation	2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. Annals of hematology, 2019, Volume: 98, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluation; Drug Substitution; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Protease Inhibitors; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide	2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications, 2019, 04-23, Volume: 10, Issue:1 Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome, Human; Humans; Ikaros Transcription Factor; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-myc; Recurrence; Survival Analysis; Thalidomide; Translocation, Genetic; Whole Genome Sequencing	2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma. International journal of hematology, 2019, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Banding; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous	2019
Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation. International journal of hematology, 2019, Volume: 110, Issue:4 Topics: Aged; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Pulse Therapy, Drug; Recurrence; Stevens-Johnson Syndrome; Transplantation, Haploidentical; Treatment Outcome	2019
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic Expert review of hematology, 2019, Volume: 12, Issue:8 Topics: Antigens, CD; Azacitidine; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Myelodysplastic Syndromes; Programmed Cell Death 1 Receptor; Recurrence; Transplantation, Homologous	2019
Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone. Annals of hematology, 2019, Volume: 98, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polycythemia; Recurrence; Salvage Therapy; Syndrome; Telangiectasis	2019
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. American journal of hematology, 2013, Volume: 88, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous	2013
Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation. International journal of hematology, 2013, Volume: 97, Issue:4 Topics: Adult; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome	2013
Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. American journal of hematology, 2013, Volume: 88, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome	2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer, 2013, Jul-01, Volume: 119, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
Designs for randomized phase II clinical trials with two treatment arms. Statistics in medicine, 2013, Nov-10, Volume: 32, Issue:25 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bias; Clinical Trials, Phase II as Topic; Endpoint Determination; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Recurrence; Research Design; Rituximab; Thalidomide; Treatment Outcome	2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. British journal of haematology, 2013, Volume: 162, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult	2013
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Venous Thrombosis	2014
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. American journal of hematology, 2014, Volume: 89, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Dexamethasone; Female; Greece; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Osteogenesis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome	2014
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:3 Topics: Aged; Bone Marrow; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Male; Positron-Emission Tomography; Recurrence; Thalidomide; Tomography, X-Ray Computed; Transplantation, Homologous	2014
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymph Nodes; Lymphoma, T-Cell; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Recurrence; Retreatment; Thalidomide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine	2014
Successful management of refractory pediatric-onset complex aphthosis with lenalidomide. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:4 Topics: Adolescent; Diagnosis, Differential; Humans; Immunologic Factors; Lenalidomide; Male; Recurrence; Stomatitis, Aphthous; Thalidomide	2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. British journal of haematology, 2014, Volume: 166, Issue:6 Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome	2014
A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide. International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:5 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Birefringence; Bone Marrow Examination; Fatal Outcome; Female; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Microscopy, Polarization; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Salvage Therapy; Thalidomide; Time Factors; Treatment Outcome	2014
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous	2014
Hepatic extramedullary disease in multiple myeloma with 17p deletion. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms	2014
Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. Annals of hematology, 2015, Volume: 94, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Survival Rate; Tertiary Care Centers; Thalidomide; Treatment Outcome; Young Adult	2015
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma. Hematological oncology, 2016, Volume: 34, Issue:1 Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult	2016
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC nephrology, 2014, Sep-30, Volume: 15 Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies	2014
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. Journal of medical case reports, 2014, Oct-02, Volume: 8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Radiotherapy, Adjuvant; Recurrence; Rituximab; Salvage Therapy; Thalidomide	2014
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Annals of hematology, 2015, Volume: 94, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure	2015
Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients. Leukemia & lymphoma, 2015, Volume: 56, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Recurrence; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A	2015
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. International journal of hematology, 2015, Volume: 101, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors; Treatment Outcome	2015
Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. European journal of haematology, 2015, Volume: 95, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Recurrence; Thalidomide; Treatment Outcome	2015
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. Leukemia & lymphoma, 2015, Volume: 56, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2015
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide	2015
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult	2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2015
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:7 Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Transplantation, Homologous	2015
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PloS one, 2015, Volume: 10, Issue:9 Topics: Aged; Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom	2015
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation. Clinical chemistry and laboratory medicine, 2016, Jun-01, Volume: 54, Issue:6 Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexamethasone; Humans; Immunoelectrophoresis; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Thalidomide	2016
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. PloS one, 2016, Volume: 11, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous	2016
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern. Circulation, 2016, Apr-05, Volume: 133, Issue:14 Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; Edema; Emergencies; Heart; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Nephrotic Syndrome; Paraproteinemias; Paraproteins; Recurrence; Syncope; Thalidomide; Torsades de Pointes; Transplantation, Autologous	2016
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome	2016
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. Journal of medical economics, 2016, Volume: 19, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Oligopeptides; Quality of Life; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States	2016
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylate Cyclase; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Signal Transduction; Thalidomide; Transfection	2016
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Blood cancer journal, 2016, 05-27, Volume: 6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Humans; L-Selectin; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Survival Analysis; Thalidomide; Vascular Cell Adhesion Molecule-1	2016
Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide. International journal of hematology, 2016, Volume: 104, Issue:3 Topics: Aged; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Remission Induction; Thalidomide; Treatment Outcome	2016
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. Hematological oncology, 2017, Volume: 35, Issue:4 Topics: Aged; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Survival Rate; Thalidomide	2017
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. Neurology, 2016, Sep-13, Volume: 87, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Prospective Studies; Recurrence; Sensory Receptor Cells; Severity of Illness Index; Thalidomide; Time Factors	2016
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. Applied health economics and health policy, 2017, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Panobinostat; Proportional Hazards Models; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome	2017
Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. Pediatric blood & cancer, 2017, Volume: 64, Issue:1 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Child, Preschool; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Lenalidomide; Male; Prognosis; Recurrence; Remission Induction; Thalidomide	2017
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome; Vorinostat	2016
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Haematologica, 2017, Volume: 102, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunoglobulins; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide	2017
Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma. Archivos de bronconeumologia, 2017, Volume: 53, Issue:6 Topics: Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Nov-15, Volume: 23, Issue:22 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Approval; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Recurrence; Thalidomide; Treatment Outcome	2017
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood cancer journal, 2017, 03-17, Volume: 7, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Drug Resistance, Neoplasm; Europe; Female; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Recurrence; Retreatment; Thalidomide; Treatment Outcome	2017
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Annals of hematology, 2009, Volume: 88, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Glucocorticoids; Heparin, Low-Molecular-Weight; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Risk Factors; Thalidomide; Thromboembolism	2009
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, 2008, Dec-01, Volume: 112, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Placebos; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2008
The current landscape of multiple myeloma treatment. Leukemia research, 2008, Volume: 32 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Patient Selection; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous	2008
Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Annals of hematology, 2009, Volume: 88, Issue:9 Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Remission Induction; Thalidomide	2009
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Thalidomide; Time Factors; Treatment Outcome	2009
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British journal of haematology, 2009, Volume: 146, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Killer Cells, Natural; Lenalidomide; Leukopenia; Multiple Myeloma; Recurrence; Salvage Therapy; T-Lymphocytes; Thalidomide; Thrombocytopenia; Treatment Outcome	2010
Lenalidomide for the treatment of relapsed multiple myeloma. The Lancet. Oncology, 2009, Volume: 10, Issue:7 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Health Care Rationing; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Recurrence; Technology Assessment, Biomedical; Thalidomide; United Kingdom	2009
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Thalidomide	2010
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia, 2009, Volume: 23, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Thalidomide	2009
Relapse/Refractory myeloma patient: potential treatment guidelines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide	2009
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide	2010
Lenalidomide-induced hypersensitivity pneumonitis. Onkologie, 2010, Volume: 33, Issue:5 Topics: Adrenal Cortex Hormones; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2010
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leukemia & lymphoma, 2010, Volume: 51, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cohort Studies; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome	2010
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. Annals of hematology, 2011, Volume: 90, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous	2011
Lenalidomide: an update on evidence from clinical trials. Blood reviews, 2010, Volume: 24 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2010
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide	2011
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. International journal of hematology, 2011, Volume: 93, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Inflammation Mediators; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2011
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Annals of hematology, 2012, Volume: 91, Issue:2 Topics: Antineoplastic Agents; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stevens-Johnson Syndrome; Thalidomide; Transplantation, Homologous	2012
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer, 2011, Nov-15, Volume: 117, Issue:22 Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Germinal Center; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prognosis; Recurrence; Thalidomide; Treatment Outcome	2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer, 2011, May-15, Volume: 117, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Thalidomide; Translocation, Genetic	2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of hematology, 2012, Volume: 91, Issue:1 Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2012
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leukemia & lymphoma, 2011, Volume: 52, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytogenetics; Dexamethasone; Humans; Immunoglobulin Isotypes; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Homologous; Treatment Outcome	2011
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed European journal of haematology, 2011, Volume: 87, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide	2011
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia, 2011, Volume: 25, Issue:10 Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Regression Analysis; Survival Analysis; Thalidomide	2011
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma. American journal of hematology, 2011, Volume: 86, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasmacytoma; Recurrence; Thalidomide	2011
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Depression; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prognosis; Recurrence; Risk Factors; Thalidomide; Treatment Outcome; Tremor	2012
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide. International journal of hematology, 2011, Volume: 94, Issue:6 Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide	2011
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome	2012
p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. American journal of clinical pathology, 2012, Volume: 137, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Canada; Cell Nucleus; Chromosomes, Human, Pair 17; Dexamethasone; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gene Deletion; Hemizygote; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Survival Rate; Thalidomide; Tumor Suppressor Protein p53	2012
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. British journal of haematology, 2012, Volume: 157, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide	2012
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome	2012
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp Vnitrni lekarstvi, 2012, Volume: 58, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous	2012
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. American journal of hematology, 2012, Volume: 87, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Humerus; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Prednisolone; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Autologous	2012
Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell cycle (Georgetown, Tex.), 2012, Jun-15, Volume: 11, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured	2012
Relapse of liver amyloidosis 6 years after autologous stem cell transplantation. American journal of hematology, 2012, Volume: 87, Issue:9 Topics: Adult; Amyloidosis; Female; Humans; Lenalidomide; Liver Diseases; Magnetic Resonance Imaging; Peripheral Blood Stem Cell Transplantation; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure	2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. International journal of hematology, 2012, Volume: 96, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Risk Factors; Thalidomide; Treatment Outcome	2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leukemia & lymphoma, 2013, Volume: 54, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome	2013
Desensitization to lenalidomide in a patient with relapsed multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome	2013
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult	2013
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica, 2013, Volume: 98, Issue:5 Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome	2013
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leukemia & lymphoma, 2013, Volume: 54, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. European journal of haematology, 2013, Volume: 90, Issue:4 Topics: Adult; Antineoplastic Agents; Complementarity Determining Regions; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Recurrence; Remission Induction; Thalidomide; Time Factors; Young Adult	2013
Multiple myeloma, version 1.2013. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat	2013
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. American journal of hematology, 2013, Volume: 88, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Positron-Emission Tomography; Radiography; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
45th Annual Meeting of the American Society of Hematology December 6-9, 2003. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase	2004
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:8 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors	2006
Thalidomide as treatment for digestive tract angiodysplasias. The Netherlands journal of medicine, 2006, Volume: 64, Issue:11 Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Lenalidomide; Male; Melena; Recurrence; Thalidomide; Treatment Outcome; von Willebrand Diseases	2006
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leukemia research, 2008, Volume: 32, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Leukemia, Plasma Cell; Male; Recurrence; Salvage Therapy; Thalidomide	2008